BusinessImmune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s LymphomaBy Nasdaq OMXOct 19, 2017, 8:05 PM UTC
BusinessBioForce Nanosciences Holdings, Inc. (BFNH) Moves Forward With Uplifting Requirements for OTCQB, Aggressively Pursues Take Over TargetsBy Nasdaq OMXOct 18, 2017, 1:15 PM UTC
BusinessWorld Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung CancerBy Nasdaq OMXOct 18, 2017, 4:11 AM UTC
BusinessImmune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma PatientsBy Nasdaq OMXOct 16, 2017, 8:16 PM UTC
BusinessInovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder CancerBy Nasdaq OMXOct 16, 2017, 11:00 AM UTC
BusinessWorld Conference on Lung Cancer Monday Press Conference: Dangers of Smoking and Lung Cancer Intervention ResearchBy Nasdaq OMXOct 16, 2017, 6:40 AM UTC
BusinessWorld Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global GuidelinesBy Nasdaq OMXOct 15, 2017, 7:26 AM UTC
BusinessInspirata Collaborates with Elsevier to Offer ExpertPath and ImmunoQuery in its Diagnostic Cockpit and Consultation PortalBy Nasdaq OMXOct 9, 2017, 10:00 AM UTC
